The proteasome and proteasome inhibitors in multiple myeloma
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationBortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationReview of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationHideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,673
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationThe proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Self-citationSonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C., Chng, W.-J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 928
Self-citationMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Self-citationRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Self-citationDimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationSan-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
Self-citationThe development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Self-citationFisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1768 · Cited by 697
Self-citationChauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Self-citationAntitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Self-citationSiegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 657
Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 645
Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
Self-citationRöllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M. (2010) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600
Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 593
Self-citationMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
Self-citationGenomic complexity of multiple myeloma and its clinical implications
Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G., & Ghobrial, I. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 560
Harousseau, J.-L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9158 · Cited by 532
The proteasome inhibitor PS-341 in cancer therapy.
Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 521
Richardson, P. G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2007) · Blood · doi:10.1182/blood-2006-08-036947 · Cited by 513
Self-citationEvaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2766 · Cited by 499
Rosiñol, L., Oriol, A., Teruel, A. I., Hernández, D., López-Jiménez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., González, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408922 · Cited by 486
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Palladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., Basset, M., Hawkins, P., Merlini, G., & Wechalekar, A. D. (2015) · Blood · doi:10.1182/blood-2015-01-620302 · Cited by 450
LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
Self-citationKumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446
Self-citationInhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics
Yang, Y., Kitagaki, J., Dai, R.-M., Tsai, Y. C., Lorick, K. L., Ludwig, R. L., Pierre, S. A., Jensen, J. P., Davydov, I. V., Oberoi, P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0568 · Cited by 441
Drugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422683 · Cited by 423
Ma, M. H., Yang, H. H., Parker, K., Manyak, S. J., Friedman, J. M., Altamirano, C. V., Wu, Z.-Q., Borad, M. J., Frantzen, M., Roussos, E., et al. (2003) · PubMed · Cited by 414
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294983 · Cited by 381
Reeder, C. B., Reece, D. E., Kukreti, V, Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N. A., Spong, J. E., Piza, J. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 372
Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.11.4079 · Cited by 367
Self-citationBortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N. C., Richardson, P. G., Carrasco, R. D., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199604 · Cited by 363
Self-citationSiegel, D., Martin, T., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., Badros, A. Z., Jagannath, S., McCulloch, L., Rajangam, K., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.089334 · Cited by 347
Lonial, S., Waller, E. K., Richardson, P. G., Jagannath, S., Orlowski, R. Z., Giver, C. R., Jaye, D. L., Francis, D., Giusti, S., Torre, C., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1173 · Cited by 340
Self-citationCatley, L., Weisberg, E., Kiziltepe, T., Tai, Y.-T., Hideshima, T., Neri, P., Tassone, P., Atadja, P., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 336
Self-citationAntimyeloma activity of heat shock protein-90 inhibition
Mitsiades, C. S. (2005) · Blood · doi:10.1182/blood-2005-03-1158 · Cited by 319
Chauhan, D., Tian, Z., Zhou, B., Kuhn, D., Orlowski, R., Raje, N., Richardson, P., & Anderson, K. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0476 · Cited by 316
Self-citationRichardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
Self-citationMoreau, P., Avet-Loiseau, H., Facon, T., Attal, M., Tiab, M., Hulin, C., Doyen, C., Garderet, L., Randriamalala, E., Araujo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355081 · Cited by 303
Roccaro, A. M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1195 · Cited by 284
Self-citationMultiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279
Moreau, P., Hulin, C., Macro, M., Caillot, D., Chaleteix, C., Roussel, M., Garderet, L., Royer, B., Brechignac, S., Tiab, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693580 · Cited by 278
Richardson, P. G., Xie, W., Mitsiades, C., Chanan-Khan, A. A., Lonial, S., Hassoun, H., Avigan, D. E., Oaklander, A. L., Kuter, D. J., Wen, P. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3087 · Cited by 274
Self-citationZhou, H.-J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., Ho, M. N., Jiang, J., Kirk, C. J., Laidig, G. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801329v · Cited by 272
Moreau, P., Chanan-Khan, A., Roberts, A. W., Agarwal, A. B., Facon, T., Kumar, S., Touzeau, C., Punnoose, E. A., Cordero, J., Munasinghe, W., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788323 · Cited by 271
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6180 · Cited by 265
Self-citationHideshima, T., Richardson, P. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 265
Self-citationAnalysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
Chanan-Khan, A., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9641 · Cited by 263
Self-citationKumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71125-8 · Cited by 262
Self-citationVij, R., Wang, M., Kaufman, J. L., Lonial, S., Jakubowiak, A. J., Stewart, A. K., Kukreti, V., Jagannath, S., McDonagh, K. T., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-03-414359 · Cited by 255
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S. V., et al. (2012) · Leukemia · doi:10.1038/leu.2011.346 · Cited by 253
Self-citationVogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 253
Self-citationBlockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Chauhan, D., Li, G., Shringarpure, R., Podar, K., Ohtake, Y., Hideshima, T., & Anderson, K. C. (2003) · PubMed · Cited by 252
Self-citationCuring myeloma at last: defining criteria and providing the evidence
Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G. J., & Crowley, J. (2014) · Blood · doi:10.1182/blood-2014-07-552059 · Cited by 235
Jakubowiak, A., Offidani, M., Pégourie, B., De La Rubia, J., Garderet, L., Laribi, K., Bosi, A., Marasca, R., Laubach, J., Mohrbacher, A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-694604 · Cited by 234
Self-citationCarfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W. I., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Gomes, C. L., et al. (2015) · Blood · doi:10.1182/blood-2015-05-643320 · Cited by 226
The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications
Burger, A. M., & Seth, A. K. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.006 · Cited by 224
Richardson, P. G., Baz, R., Wang, M., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D., Liu, G., Yu, J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 203
Self-citationKortuem, K. M., & Stewart, A. K. (2013) · Blood · doi:10.1182/blood-2012-10-459883 · Cited by 200
Kumar, S. K., Bensinger, W. I., Zimmerman, T. M., Reeder, C. B., Berenson, J. R., Berg, D., Hui, A.-M., Gupta, N., Di Bacco, A., Yu, J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548941 · Cited by 197
Current treatment landscape for relapsed and/or refractory multiple myeloma
Dimopoulos, M. A., Richardson, P. G., Moreau, P., & Anderson, K. C. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.200 · Cited by 195
Self-citationReeder, C. B., Reece, D. E., Kukreti, V., Chen, C., Trudel, S., Laumann, K., Hentz, J., Pirooz, N. A., Piza, J. G., Tiedemann, R., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271676 · Cited by 190
Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4918 · Cited by 190
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189
Shah, J. J., Jakubowiak, A. J., O'Connor, O. A., Orlowski, R. Z., Harvey, R. D., Smith, M. R., Lebovic, D., Diefenbach, C., Kelly, K., Hua, Z., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1237 · Cited by 189
Unexpected cardiotoxicity in haematological bortezomib treated patients
Orciuolo, E., Buda, G., Cecconi, N., Galimberti, S., Versari, D., Cervetti, G., Salvetti, A., & Petrini, M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06659.x · Cited by 185
Richardson, P. G., Xie, W., Jagannath, S., Jakubowiak, A., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Schlossman, R. L., Munshi, N. C., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517276 · Cited by 182
Self-citationBortezomib resistance in multiple myeloma is associated with increased serine synthesis
Zaal, E. A., Wu, W., Jansen, G., Zweegman, S., Cloos, J., & Berkers, C. R. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0169-9 · Cited by 182
Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia
Leblond, V., Kastritis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., García-Sanz, R., Gertz, M., Kimby, E., Kyriakou, C., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711234 · Cited by 181
Vij, R., Siegel, D. S., Jagannath, S., Jakubowiak, A. J., Stewart, A. K., McDonagh, K., Bahlis, N., Belch, A., Kunkel, L. A., Wear, S., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09232.x · Cited by 177
Progress and Paradigms in Multiple Myeloma
Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 169
Self-citationJagannath, S., Richardson, P. G. G., Barlogie, B., Berenson, J. R., Singhal, S., Irwin, D. H., Srkalović, G., Schenkein, D. P., Esseltine, D. L., & Anderson, K. C. (2006) · PubMed · Cited by 167
Self-citationCommunity-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Niesvizky, R., Flinn, I. W., Rifkin, R. M., Gabrail, N. Y., Charu, V., Clowney, B., Essell, J. H., Gaffar, Y., Warr, T. A., Neuwirth, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.7618 · Cited by 162
Miguel, J. F. S., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30147-8 · Cited by 158
Self-citationOcio, E. M., Vilanova, D., Atadja, P., Maiso, P., Crusoe, E., Fernandez-Lazaro, D., Garayoa, M., San-Segundo, L., Hernandez-Iglesias, T., de Alava, E., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.015495 · Cited by 157
Wang, X., Mazurkiewicz, M., Hillert, E.-K., Olofsson, M. H., Pierrou, S., Hillertz, P., Gullbo, J., Selvaraju, K., Paulus, A., Akhtar, S., et al. (2016) · Scientific Reports · doi:10.1038/srep26979 · Cited by 154
Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedé, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563759 · Cited by 153
Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A. T., Schurich, B., Hielscher, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.80 · Cited by 151
Soriano, G. P., Besse, L., Li, N., Kraus, M., Besse, A., Meeuwenoord, N., Bader, J., Everts, B., den Dulk, H., Overkleeft, H. S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.102 · Cited by 145
Hideshima, T., Qi, J., Paranal, R. M., Tang, W., Greenberg, E., West, N., Colling, M. E., Estiu, G., Mazitschek, R., Perry, J. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608067113 · Cited by 144
Self-citationDimopoulos, M. A., Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kropff, M., Spicka, I., Palumbo, A., Wu, K. L., et al. (2011) · European Journal of Haematology · doi:10.1111/j.1600-0609.2010.01533.x · Cited by 142
Self-citationMellqvist, U.-H., Gimsing, P., Hjertner, O., Lenhoff, S., Laane, E., Remes, K., Steingrimsdottir, H., Abildgaard, N., Ahlberg, L., Blimark, C., et al. (2013) · Blood · doi:10.1182/blood-2012-11-464503 · Cited by 139
Deubiquitinases (DUBs) and DUB inhibitors: a patent review
Farshi, P., Deshmukh, R. R., Nwankwo, J. O., Arkwright, R. T., Cvek, B., Liu, J., & Dou, Q. P. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1056737 · Cited by 138
Diagnosis and Management of Waldenström Macroglobulinemia
Kapoor, P., Ansell, S. M., Fonseca, R., Chanan-Khan, A. A., Kyle, R. A., Kumar, S. K., Mikhael, J. R., Witzig, T. E., Mauermann, M. L., Dispenzieri, A. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5763 · Cited by 137
Grandin, E. W., Ky, B., Cornell, R. F., Carver, J. R., & Lenihan, D. J. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.11.008 · Cited by 132
Richardson, P. G., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2016) · Blood · doi:10.1182/blood-2015-09-665018 · Cited by 131
Self-citationAvet‐Loiseau, H., Fonseca, R., Siegel, D. S. D., Dimopoulos, M. A., Špıčka, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V. S., Mihaylov, G. G., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707596 · Cited by 131
Ling, S. C. W., Lau, E. K. K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P. J., Harrison, S., Fleming, S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.043331 · Cited by 130
Arnulf, B., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., van de Velde, H., Feng, H., Cakana, A., Deraedt, W., & Moreau, P. (2012) · Haematologica · doi:10.3324/haematol.2012.067793 · Cited by 127
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Sanchorawala, V., Palladini, G. O., Kukreti, V., Zonder, J. A., Cohen, A. D., Seldin, D. C., Dispenzieri, A. A., Jaccard, A., Schönland, S. O., Berg, D. T., et al. (2017) · Blood · doi:10.1182/blood-2017-03-771220 · Cited by 124
Petrucci, M. T., Giraldo, P., Corradini, P., Teixeira, A., Dimopoulos, M. A., Blau, I. W., Drach, J., Angermund, R., Allietta, N., Broer, E., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12198 · Cited by 123
Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A. P., Rosiñol, L., Nagler, A., Yong, K., Oriol, A., Minařík, J., Pour, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.176 · Cited by 122
Bešše, A., Stolze, S. C., Rasche, L., Weinhold, N., Morgan, G. J., Kraus, M., Bader, J. E., Overkleeft, H. S., Bešše, L., & Driessen, C. (2017) · Leukemia · doi:10.1038/leu.2017.212 · Cited by 122
A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma
Miguel, J. F. S., Bladé, J., Boccadoro, M., Cavenagh, J. D., Glasmacher, A., Jagannath, S., Lonial, S., Orlowski, R. Z., Sonneveld, P., & Ludwig, H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-1-51 · Cited by 120
Jagannathan, S., Abdel-Malek, M. A. Y., Malek, E., Vad, N. M., Latif, T., Anderson, K. C., & Driscoll, J. J. (2015) · Leukemia · doi:10.1038/leu.2015.157 · Cited by 118
Self-citationMateos, M., Oriol, A., Martínez‐López, J., Teruel, A. I., de la Guía, A. L., López, J., Bengoechea, E., Pérez, M., Martínez, R., Palomera, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-573733 · Cited by 110
Targeting Ubiquitination for Cancer Therapies
Morrow, J. K., Lin, H., Sun, S., & Zhang, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.148 · Cited by 110
Cardiac and renal complications of carfilzomib in patients with multiple myeloma
Dimopoulos, M. A., Ρούσσου, Μ., Gavriatopoulou, M., Psimenou, E., Ziogas, D. C., Eleutherakis‐Papaiakovou, E., Fotiou, D., Migkou, M., Kanellias, N., Panagiotidis, I., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003269 · Cited by 110
Vickrey, E., Allen, S., Mehta, J., & Singhal, S. (2008) · Cancer · doi:10.1002/cncr.24006 · Cited by 108
Mikhael, J. R., Belch, A. R., Prince, H. M., Lucio, M. N., Maiolino, A., Corso, A., Petrucci, M. T., Musto, P., Komarnicki, M., & Stewart, A. K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07409.x · Cited by 108
Chauhan, D., Singh, A. V., Ciccarelli, B., Richardson, P. G., Palladino, M. A., & Anderson, K. C. (2010) · Blood · doi:10.1182/blood-2009-03-213009 · Cited by 108
Self-citationLacy, M. Q., & McCurdy, A. B. R. (2013) · Blood · doi:10.1182/blood-2013-05-484782 · Cited by 104
Mishima, Y., Santo, L., Eda, H., Cirstea, D., Nemani, N., Yee, A. J., O'Donnell, E., Selig, M. K., Quayle, S. N., Arastu‐Kapur, S., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13315 · Cited by 103
Ludwig, H., Kasparu, H., Leitgeb, C., Rauch, E., Linkesch, W., Zojer, N., Greil, R., Seebacher, A., Pour, L., Weißmann, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-521468 · Cited by 100
Lonial, S., Richardson, P. G., San Miguel, J., Sonneveld, P., Schuster, M. W., Bladé, J., Cavenagh, J., Rajkumar, S. V., Jakubowiak, A. J., Esseltine, D., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07321.x · Cited by 94
Self-citationRecent improvement in survival of patients with multiple myeloma: variation by ethnicity
Pulte, D. D., Redaniel, M. T., Brenner, H., Jansen, L., & Jeffreys, M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.827188 · Cited by 91
Proteasome function is required for platelet production
Shi, D., Smith, M. C. P., Campbell, R. A., Zimmerman, P. W., Franks, Z. B., Kraemer, B. F., Machlus, K. R., Jing, L., Kamba, P., Schwertz, H., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75247 · Cited by 89
Wang, M., Han, X., Zhang, L., Yang, J., Qian, J. F., Shi, Y., Kwak, L. W., Romaguera, J. E., & Yi, Q. (2007) · Leukemia · doi:10.1038/sj.leu.2404959 · Cited by 87
Richardson, P. G. G., Zimmerman, T. M., Hofmeister, C. C., Talpaz, M., Chanan-Khan, A. A., Kaufman, J. L., Laubach, J. P., Chauhan, D., Jakubowiak, A. J., Reich, S. D., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686378 · Cited by 85
Self-citationPhase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
Kumar, S. K., LaPlant, B. R., Roy, V., Reeder, C. B., Lacy, M. Q., Gertz, M. A., Laumann, K. M., Thompson, M. A., Witzig, T. E., Buadi, F. K., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.60 · Cited by 84
Danhof, S., Schreder, M., Rasche, L., Strifler, S., Einsele, H., & Knop, S. T. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12677 · Cited by 83
The Immunoproteasome as a Target in Hematologic Malignancies
Kuhn, D. J., & Orlowski, R. Z. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.003 · Cited by 82
Lendvai, N., Hilden, P., Devlin, S., Landau, H., Hassoun, H., Lesokhin, A. M., Tsakos, I., Redling, K., Koehne, G., Chung, D. J., et al. (2014) · Blood · doi:10.1182/blood-2014-02-556308 · Cited by 82
The proteasome inhibitor CEP‐18770 enhances the anti‐myeloma activity of bortezomib and melphalan
Sanchez, E., Li, M., Steinberg, J. A., Wang, C., Shen, J., Bonavida, B., Li, Z., Chen, H., & Berenson, J. R. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08008.x · Cited by 81
Ashley, J. D., Quinlan, C. J., Schroeder, V. A., Suckow, M. A., Pizzuti, V. J., Kiziltepe, T., & Bilgiçer, B. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0867 · Cited by 81
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
Qiang, Y., Ye, S., Chen, Y., Buros, A. F., Edmonson, R., van Rhee, F., Barlogie, B., Epstein, J., Morgan, G. J., & Davies, F. E. (2016) · Blood · doi:10.1182/blood-2016-03-706077 · Cited by 81
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Williamson, M. J., Blank, J. L., Bruzzese, F. J., Cao, Y., Daniels, J. S., Dick, L. R., LaButti, J. N., Mazzola, A. M., Patil, A. D., Reimer, C., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0185 · Cited by 80
Bockorny, M., Chakravarty, S., Schulman, P. M., Bockorny, B., & Bona, R. (2012) · Acta Haematologica · doi:10.1159/000340050 · Cited by 80
Harrison, S. J., Mainwaring, P. N., Price, T. J., Millward, M., Padrik, P., Underhill, C. R., Cannell, P., Reich, S. D., Trikha, M., & Spencer, A. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2616 · Cited by 79
Moreau, P., Joshua, D., Chng, W.-J., Palumbo, A., Goldschmidt, H., Hájek, R., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., et al. (2017) · Leukemia · doi:10.1038/leu.2016.186 · Cited by 78
Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A., Lust, J. A., et al. (2017) · Blood · doi:10.1182/blood-2017-05-782961 · Cited by 78
Self-citationBiologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Hideshima, T., Chauhan, D., Kiziltepe, T., Ikeda, H., Okawa, Y., Podar, K., Raje, N., Protopopov, A., Munshi, N. C., Richardson, P. G., et al. (2009) · Blood · doi:10.1182/blood-2008-06-161505 · Cited by 75
Self-citationCarfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Rosenthal, A., Luthi, J., Belohlavek, M., Kortüm, K. M., Mookadam, F., Mayo, A., Fonseca, R., Bergsagel, P. L., Reeder, C. B., Mikhael, J. R., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2015.112 · Cited by 75
Wang, X., Stafford, W. C., Mazurkiewicz, M., Fryknäs, M., Brjnic, S., Zhang, X., Gullbo, J., Larsson, R. L., Arnér, E. S. J., D’Arcy, P., et al. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.091322 · Cited by 73
Dimopoulos, M. A., Stewart, A. K., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Mihaylov, G. G., Goranova-Marinova, V. S., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14549 · Cited by 73
Reece, D. E., Hegenbart, U., Sanchorawala, V., Merlini, G., Palladini, G. O., Bladé, J., Fermand, J., Hassoun, H., Heffner, L. T., Kukreti, V., et al. (2014) · Blood · doi:10.1182/blood-2014-04-568329 · Cited by 69
Oran, B., Jorgensen, J., Marín, D., Wang, S., Ahmed, S., Alousi, A. M., Andersson, B. S., Bashir, Q., Bassett, R. L., Lyons, G. R., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.144253 · Cited by 69
Dimopoulos, M. A., Stewart, A. K., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Mihaylov, G. G., Goranova‐Marinova, V., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.31 · Cited by 69
Dytfeld, D., Łuczak, M., Wróbel, T., Usnarska‐Zubkiewicz, L., Brzeźniakiewicz‐Janus, K., Jamroziak, K., Giannopoulos, K., Przybyłowicz-Chalecka, A., Ratajczak, B., Czerwińska-Rybak, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11059 · Cited by 67
Sonneveld, P., Asselbergs, E., Zweegman, S., van der Holt, B., Kersten, M. J., Vellenga, E., van Marwijk-Kooy, M., Broyl, A., de Weerdt, O., Lonergan, S., et al. (2015) · Blood · doi:10.1182/blood-2014-05-576256 · Cited by 64
Kumar, S. K., LaPlant, B. R., Reeder, C. B., Roy, V., Halvorson, A. E., Buadi, F. K., Gertz, M. A., Bergsagel, P. L., Dispenzieri, A. A., Thompson, M. A., et al. (2016) · Blood · doi:10.1182/blood-2016-05-717769 · Cited by 60
Kumar, S. K., Moreau, P., Hari, P., Mateos, M., Ludwig, H., Shustik, C., Masszi, T., Spencer, A. G., Hájek, R., Romeril, K. R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14733 · Cited by 59
Self-citationHideshima, T., & Anderson, K. C. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.006 · Cited by 55
Self-citationHideshima, T., Chauhan, D., Ishitsuka, K., Yasui, H., Raje, N. S., Kumar, S. K., Podar, K., Mitsiades, C. S., Hideshima, H., Bonham, L., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208522 · Cited by 52
Self-citationNF-κB dysregulation in multiple myeloma
Matthews, G. M., Simoes, R. D. M., Dhimolea, E., Sheffer, M., Gandolfi, S., Dashevsky, O., Sorrell, J., & Mitsiades, C. S. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.005 · Cited by 52
Self-citationOrlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hájek, R., Spencer, A. G., Robak, T., Dmoszyńska, A., Horvath, N., Špıčka, I., et al. (2016) · Cancer · doi:10.1002/cncr.30026 · Cited by 50
Das, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13780 · Cited by 49
Self-citationWhen Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response
Shah, S. P., Lonial, S., & Boise, L. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0135 · Cited by 49
Laubach, J. P., Moslehi, J. J., Francis, S. A., San Miguel, J. F., Sonneveld, P., Orlowski, R. Z., Moreau, P., Rosiñol, L., Faber, E. A., Voorhees, P., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14708 · Cited by 49
Self-citationMitra, A., Harding, T., Mukherjee, U. K., Jang, J. S., Li, Y., Res, H., Jen, J., Sonneveld, P., Kumar, S. K., Kuehl, W. M., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.56 · Cited by 48
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions
Moreau, P., & de Wit, E. (2017) · British Journal of Haematology · doi:10.1111/bjh.14780 · Cited by 46
Dytfeld, D., Jasielec, J., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T., Detweiler-Short, K., Stockerl-Goldstein, K., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.110395 · Cited by 45
Minařík, J., Pavlíček, P., Pour, L., Pika, T., Maisnar, V., Špıčka, I., Jarkovský, J., Krejčí, M., Bačovský, J., Radocha, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123866 · Cited by 43
Reeder, C. B., Reece, D. E., Kukreti, V., Mikhael, J. R., Chen, C., Trudel, S., Laumann, K., Vohra, H., Fonseca, R., Bergsagel, P. L., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13004 · Cited by 42
Targeting the UPS as therapy in multiple myeloma
Chauhan, D., Bianchi, G., & Anderson, K. C. (2008) · BMC Biochemistry · doi:10.1186/1471-2091-9-s1-s1 · Cited by 40
Self-citationKumar, A., Ito, A., Hirohama, M., Yoshida, M., & Zhang, K. Y. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.030 · Cited by 40
Bortezomib and heart failure: case‐report and review of the French P harmacovigilance database
Honton, B., Despas, F., Dumonteil, N., Rouvellat, C., Roussel, M., Carrié, D., Galinier, M., Montastruc, J. L., & Pathak, A. (2013) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12039 · Cited by 39
Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors
Jouni, H., Aubry, M. C., Lacy, M. Q., Rajkumar, S. V., Kumar, S. K., Frye, R. L., & Herrmann, J. (2016) · American Journal of Hematology · doi:10.1002/ajh.24608 · Cited by 37
Sonneveld, P., Salwender, H.-J., van der Holt, B., el Jarari, L., Bertsch, U., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M. G., et al. (2015) · Blood · doi:10.1182/blood.v126.23.27.27 · Cited by 37
Richardson, P. G. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S. D., Lonial, S., Laubach, J. P., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J. M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.173 · Cited by 37
Self-citationFacon, T. T. F., Lee, J. H., Moreau, P., Niesvizky, R., Dimopoulos, M. A., Hájek, R., Osman, M., Aggarwal, S. K., Klippel, Z. K., & Miguel, J. F. S. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.03.045 · Cited by 36
Muz, B., Kusdono, H. D., Azab, F., de la Puente, P., Federico, C., Fiala, M., Vij, R., Salama, N. N., & Azab, A. K. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1319052 · Cited by 35
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes
Murai, K., Kowata, S., Shimoyama, T., Yashima‐Abo, A., Fujishima, Y., Ito, S., & Ishida, Y. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12342 · Cited by 33
Dimopoulos, M. A., Orlowski, R. Z., Facon, T. T. F., Sonneveld, P., Anderson, K. C., Beksaç, M., Benboubker, L., Roddie, H., Potamianou, A., Couturier, C., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.112037 · Cited by 33
Self-citationCao, M.-N., Zhou, Y., Gao, A., Cao, J., Gao, L., Li, S., Xu, L., Su, M., Cao, X., Han, M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.02.006 · Cited by 33
Siegel, D. S. D., Dimopoulos, M. A., Jagannath, S., Goldschmidt, H., Durrant, S., Kaufman, J. L., Leleu, X. P., Nagler, A., Offner, F. C., Graef, T. T., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.042 · Cited by 33
Self-citationProteasome inhibitor-induced gastrointestinal toxicity
Stansborough, R. L., & Gibson, R. J. (2017) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000266 · Cited by 33
Sun, Z., Zheng, F., Wu, S., Liu, Y., Guo, H., & Liu, Y. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.018 · Cited by 31
Gao, L., Gao, M., Yang, G., Yi, T., Kong, Y., Yang, R., Meng, X., Ai, G., Wei, R., Wu, H., et al. (2015) · BioMed Research International · doi:10.1155/2015/459052 · Cited by 29
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
Boudreault, J., Touzeau, C., & Moreau, P. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1285694 · Cited by 26
Fristedt, C., Lub, S., Agarwal, P., Arngården, L., Hammarberg, A., Maes, K., Valckenborgh, E. V., Vanderkerken, K., & Jernberg‐Wiklund, H. (2015) · Oncotarget · doi:10.18632/oncotarget.4139 · Cited by 24
Ghobrial, I. M., Savona, M. R., Vij, R., Siegel, D. S. D., Badros, A. Z., Kaufman, J. L., Raje, N. S., Jakubowiak, A. J., Obreja, M., & Berdeja, J. G. (2016) · Blood · doi:10.1182/blood.v128.22.2110.2110 · Cited by 24
Shah, J. J., Niesvizky, R., Stadtmauer, E. A., Rifkin, R. M., Berenson, J., Berdeja, J. G., Sharman, J. P., Lyons, R. M., Klippel, Z. K., Wong, H. L., et al. (2015) · Blood · doi:10.1182/blood.v126.23.378.378 · Cited by 23
Proteasome Inhibitors as a Potential Cause of Heart Failure
Koulaouzidis, G., & Lyon, A. R. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.12.001 · Cited by 21
Waal, E. G. M. D., de Munck, L., Hoogendoorn, M., Woolthuis, G., van der Velden, A. W. G., Tromp, Y., Vellenga, E., & Hovenga, S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13653 · Cited by 20
New and developing therapies for AL amyloidosis
Zumbo, G., Sadeghi‐Alavijeh, O., Hawkins, P. N., & Fontana, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1274971 · Cited by 17
Kumar, S. K., Ma, E., Engebretson, A., Buadi, F. K., Lacy, M. Q., Dispenzieri, A. A., Duh, M. S., Lafeuille, M., Lefèbvre, P., Cheng, W. Y., et al. (2015) · Leukemia · doi:10.1038/leu.2015.225 · Cited by 16
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Musto, P., & Montefusco, V. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1196127 · Cited by 15
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
Larsen, J. T., & Kumar, S. K. (2015) · Rare Cancers and Therapy · doi:10.1007/s40487-015-0009-4 · Cited by 14
Nooka, A. K. (2013) · PubMed · Cited by 13
Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia
Gavriatopoulou, M., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1275561 · Cited by 13
Resistance to Proteasome Inhibitors in Multiple Myeloma
Cottini, F., Guidetti, A., Prada, C. P., Hideshima, T., Maglio, M. E., Varga, C., Chauhan, D., Laubach, J. P., Anderson, K. C., & Richardson, P. G. G. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-06752-0_2 · Cited by 10
Self-citation
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
The safety of bortezomib for the treatment of multiple myeloma
Cengiz Seval, G., & Beksac, M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1513487 · Cited by 117
Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83
Self-citation
Metadata
- Authors
- Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2017-12
- Volume
- 36
- Issue
- 4
- Pages
- 561-584
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2773382289
- Cited by
- 340
- References
- 201
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.